Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.
2.

Breast cancer prevention with selective estrogen receptor modulators: a perspective.

Pritchard KI.

Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.

PMID:
11795385
3.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
4.

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF.

Breast J. 2001 Sep-Oct;7(5):311-20. Review.

PMID:
11906441
5.

Chemoprevention of breast cancer in the older patient.

Minton SE.

Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review.

PMID:
10680075
6.

Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

Lo SS, Vogel VG.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):97-111. Review.

PMID:
14687600
7.
8.

Prevention of hormone-related cancers: breast cancer.

Dunn BK, Wickerham DL, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.

PMID:
15637398
9.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
10.

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

Lee WL, Cheng MH, Chao HT, Wang PH.

Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Review.

11.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
12.

National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S. Review.

13.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

14.

Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.

Zujewski J.

Environ Mol Mutagen. 2002;39(2-3):264-70. Review.

PMID:
11921197
15.

SERMs for the treatment and prevention of breast cancer.

Swaby RF, Sharma CG, Jordan VC.

Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. Review.

PMID:
17440819
16.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
17.

Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.

Bao T, Prowell T, Stearns V.

Am J Ther. 2006 Jul-Aug;13(4):337-48. Review.

PMID:
16858170
18.

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

Dunn BK, Ford LG.

Eur J Cancer Prev. 2007 Jun;16(3):232-42. Review.

PMID:
17415094
19.

Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

Park WC, Jordan VC.

Trends Mol Med. 2002 Feb;8(2):82-8. Review.

PMID:
11815274
20.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794

Supplemental Content

Support Center